U.S. regulators dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks.
Flu season is drawing attention to mandatory paid sick leave for the 40 percent of American private-sector workers — more than 40 million people — who don't have it.
New data from the CDC shows doctor visits related to the flu continued to decline last week. Robert Kelly, president of New York Presbyterian Hospital, weighs in.
This flu season is striking early, but is it really an epidemic? Tevi Troy, Romney Health Care Policy adviser, weighs in.
The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.
Making the health care system function better could save $2 trillion on health costs over the next decade, Dr. David Blumenthal, Commonwealth Fund president, told CNBC on Friday.
Widespread influenza activity has afflicted 47 states, according to the CDC. Phil Hosbach, VP of Immunization Policy, discusses whether people should be worried about dwindling supplies.
Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
Peter Suderman, Reason Magazine, explains whether insurance company premiums are rising under so-called Obamacare. Meanwhile Michael Farr, Farr, Miller & Washington, discusses what that means for health stocks.
The Affordable Care Act will go far to rescue the generation hardest hit by rising health-care costs, including 8.6 million Boomers without health insurance.
States are setting up health insurance exchanges, reports CNBC's Bertha Coombs. Max Nisen, Business Insider, also weighs in.
It's hard to see how lawmakers can avoid touching health insurance if they want to eliminate loopholes and curtail deductions so as to raise revenue and lower tax rates.
Toby Cosgrove, CEO & president at The Cleveland Clinic, explains how "fiscal cliff" cuts could severely impact the health care industry.
Health care costs, especially in drug development remains high despite advancements in medicine. But as Taher Abbasi, CEO of Cellworks tells CNBC's Martin Soong, that is all set to change with innovation.
Christopher Viehbacher, CEO, Sanofi says that as cost rises, the firm is growing its emerging-markets business outside of the BRIC nations.
Merck reported higher-than-expected quarterly results on Friday and said it continued to expect full-year revenue to be at or near 2011 levels on a constant currency basis.
The managing partner of Google's venture capital, Bill Maris, says under-investment in health sciences is short-sighted.
The goal is to enable physicians and pharmaceutical companies to use complex genetic data to tailor treatment on an individual basis, according to Mike Pellini, CEO of Foundation Medical.
Qualcomm's CEO Paul Jacobs says the smart phone will become a focal point for wirelessly connecting medical devices, diagnostics and sensors, and providing near real-time information.